{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:17:08Z","timestamp":1790248628111,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,6,11]],"date-time":"2015-06-11T00:00:00Z","timestamp":1433980800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12917-015-0446-1","type":"journal-article","created":{"date-parts":[[2015,6,10]],"date-time":"2015-06-10T15:28:31Z","timestamp":1433950111000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma"],"prefix":"10.1186","volume":"11","author":[{"given":"Heather L.","family":"Gardner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl A.","family":"London","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta A.","family":"Portela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona P.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Clifford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas H.","family":"Thamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Vail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Crawford-Jakubiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura D.","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,11]]},"reference":[{"key":"446_CR1","first-page":"307","volume":"40","author":"CR Dorn","year":"1968","unstructured":"Dorn CR, Taylor DO, Schneider R, Hibbard HH, Klauber MR. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst. 1968;40:307\u201318.","journal-title":"J Natl Cancer Inst"},{"key":"446_CR2","first-page":"785","volume-title":"Withrow and MacEwen's Small Animal Clinical Oncology","author":"DH Thamm","year":"2007","unstructured":"Thamm DH, Miscellaneous T. In: Withrow SJ, Vail DM, editors. Withrow and MacEwen's Small Animal Clinical Oncology. 4th ed. St. Louis: W B Saunders Co; 2007. p. 785\u201395 [Hemangiosarcoma].","edition":"4"},{"key":"446_CR3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2460\/javma.1985.186.01.56","volume":"186","author":"NO Brown","year":"1985","unstructured":"Brown NO, Patnaik AK, MacEwen EG. Canine hemangiosarcoma: retrospective analysis of 104 cases. J Am Vet Med Assoc. 1985;186:56\u20138.","journal-title":"J Am Vet Med Assoc"},{"key":"446_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1939-1676.1997.tb00085.x","volume":"11","author":"WL Spangler","year":"1997","unstructured":"Spangler WL, Spangler WL, Kass PH, Kass PH. Pathologic factors affecting postsplenectomy survival in dogs. J Vet Intern Med. 1997;11:166\u201371.","journal-title":"J Vet Intern Med"},{"key":"446_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.5326\/15473317-34-5-417","volume":"34","author":"CA Wood","year":"1998","unstructured":"Wood CA, Moore AS, Gliatto JM, Ablin LA, Berg RJ, Rand WM. Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991\u20131993). J Am Anim Hosp Assoc. 1998;34:417\u201321.","journal-title":"J Am Anim Hosp Assoc"},{"key":"446_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1939-1676.1991.tb00943.x","volume":"5","author":"AS Hammer","year":"1991","unstructured":"Hammer AS, Couto CG, Filppi J, Getzy D, Shank K. Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma. J Vet Intern Med. 1991;5:160\u20136.","journal-title":"J Vet Intern Med"},{"key":"446_CR7","first-page":"237","volume":"54","author":"SA Kahn","year":"2013","unstructured":"Kahn SA, Mullin CM, de Lorimier L-P, Burgess KE, Risbon RE, Fred III RM, et al. Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study. Canadian Veterinary J. 2013;54:237\u201342.","journal-title":"Canadian Veterinary J"},{"key":"446_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1939-1676.1996.tb02085.x","volume":"10","author":"GK Ogilvie","year":"1996","unstructured":"Ogilvie GK, Powers BE, Mallinckrodt CH, Withrow SJ. Surgery and doxorubicin in dogs with hemangiosarcoma. J Vet Intern Med. 1996;10:379\u201384.","journal-title":"J Vet Intern Med"},{"key":"446_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1939-1676.2000.tb02247.x","volume":"14","author":"K Sorenmo","year":"2000","unstructured":"Sorenmo K, Duda L, Barber L, Cronin K, Sammarco C, Usborne A, et al. Canine hemangiosarcoma treated with standard chemotherapy and minocycline. J Vet Intern Med. 2000;14:395\u20138.","journal-title":"J Vet Intern Med"},{"key":"446_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1939-1676.2004.tb00162.x","volume":"18","author":"KU Sorenmo","year":"2004","unstructured":"Sorenmo KU, Baez JL, Clifford CA, Mauldin E, Overley B, Skorupski K, et al. Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma. J Vet Intern Med. 2004;18:209\u201313.","journal-title":"J Vet Intern Med"},{"key":"446_CR11","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1939-1676.1993.tb01033.x","volume":"7","author":"KU Sorenmo","year":"1993","unstructured":"Sorenmo KU, Jeglum KA, Helfand SC. Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide. J Vet Intern Med. 1993;7:370\u20136.","journal-title":"J Vet Intern Med"},{"key":"446_CR12","first-page":"1165","volume":"1","author":"DM Vail","year":"1995","unstructured":"Vail DM, MacEwen EG, Kurzman ID, Dubielzig RR, Helfand SC, Kisseberth WC, et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res. 1995;1:1165\u201370.","journal-title":"Clin Cancer Res"},{"key":"446_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1939-1676.2007.tb02936.x","volume":"21","author":"LW U\u2019Ren","year":"2007","unstructured":"U\u2019Ren LW, Biller BJ, Elmslie RE, Thamm DH, Dow SW. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J Vet Intern Med. 2007;21:113\u201320.","journal-title":"J Vet Intern Med"},{"key":"446_CR14","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/j.1939-1676.2007.tb03019.x","volume":"21","author":"S Lana","year":"2007","unstructured":"Lana S, U\u2019ren L, Plaza S, Elmslie R, Gustafson D, Morley P, et al. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med. 2007;21:764\u20139.","journal-title":"J Vet Intern Med"},{"key":"446_CR15","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/j.1939-1676.2007.tb01958.x","volume":"21","author":"K Sorenmo","year":"2007","unstructured":"Sorenmo K, Samluk M, Clifford C, Baez J, Barrett JS, Poppenga R, et al. Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma. J Vet Intern Med. 2007;21:1347\u201354.","journal-title":"J Vet Intern Med"},{"key":"446_CR16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1593\/tlo.12307","volume":"6","author":"EB Dickerson","year":"2013","unstructured":"Dickerson EB, Marley K, Edris W, Tyner JW, Schalk V, Macdonald V, et al. Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-\u03b2 and Src in Tumor Growth. Transl Oncol. 2013;6:158\u201368.","journal-title":"Transl Oncol"},{"key":"446_CR17","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/labinvest.3700080","volume":"84","author":"SP Fosmire","year":"2004","unstructured":"Fosmire SP, Dickerson EB, Scott AM, Bianco SR, Pettengill MJ, Meylemans H, et al. Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium. Lab Invest. 2004;84:562\u201372.","journal-title":"Lab Invest"},{"key":"446_CR18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/1471-2407-9-363","volume":"9","author":"A Kodama","year":"2009","unstructured":"Kodama A, Sakai H, Matsuura S, Murakami M, Murai A, Mori T, et al. Establishment of canine hemangiosarcoma xenograft models expressing endothelial growth factors, their receptors, and angiogenesis-associated homeobox genes. BMC Cancer. 2009;9:363.","journal-title":"BMC Cancer"},{"key":"446_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1476-5829.2012.00335.x","volume":"10","author":"SE Lyles","year":"2012","unstructured":"Lyles SE, Milner RJ, Kow K, Salute ME. In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines. Vet Comp Oncol. 2012;10:223\u201335.","journal-title":"Vet Comp Oncol"},{"key":"446_CR20","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1186\/1471-2407-10-619","volume":"10","author":"BA Tamburini","year":"2010","unstructured":"Tamburini BA, Phang TL, Fosmire SP, Scott MC, Trapp SC, Duckett MM, et al. Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma. BMC Cancer. 2010;10:619.","journal-title":"BMC Cancer"},{"key":"446_CR21","doi-asserted-by":"publisher","first-page":"e5549","DOI":"10.1371\/journal.pone.0005549","volume":"4","author":"BA Tamburini","year":"2009","unstructured":"Tamburini BA, Trapp S, Phang TL, Schappa JT, Hunter LE, Modiano JF. Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed. PLoS One. 2009;4:e5549.","journal-title":"PLoS One"},{"key":"446_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.rvsc.2005.09.005","volume":"81","author":"DH Thamm","year":"2006","unstructured":"Thamm DH, Dickerson EB, Akhtar N, Lewis R, Auerbach R, Helfand SC, et al. Biological and molecular characterization of a canine hemangiosarcoma-derived cell line. Res Vet Sci. 2006;81:76\u201386.","journal-title":"Res Vet Sci"},{"key":"446_CR23","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1354\/vp.43-6-971","volume":"43","author":"K Yonemaru","year":"2006","unstructured":"Yonemaru K, Sakai H, Murakami M, Yanai T, Masegi T. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and their receptors (flt-1, flk-1, and flg-1) in canine vascular tumors. Vet Pathol. 2006;43:971\u201380.","journal-title":"Vet Pathol"},{"key":"446_CR24","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1158\/1535-7163.MCT-12-0893","volume":"12","author":"NJ Andersen","year":"2013","unstructured":"Andersen NJ, Nickoloff BJ, Dykema KJ, Boguslawski EA, Krivochenitser RI, Froman RE, et al. Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma. Mol Cancer Ther. 2013;12:1701\u201314.","journal-title":"Mol Cancer Ther"},{"key":"446_CR25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1476-5829.2012.00325.x","volume":"10","author":"K Marley","year":"2012","unstructured":"Marley K, Maier CS, Helfand SC. Phosphotyrosine enrichment identifies focal adhesion kinase and other tyrosine kinases for targeting in canine hemangiosarcoma. Vet Comp Oncol. 2012;10:214\u201322.","journal-title":"Vet Comp Oncol"},{"key":"446_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1746-6148-8-128","volume":"8","author":"A Murai","year":"2012","unstructured":"Murai A, Asa SA, Kodama A, Hirata A, Yanai T, Sakai H. Constitutive phosphorylation of the mTORC2\/Akt\/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines. BMC Vet Res. 2012;8:128.","journal-title":"BMC Vet Res"},{"key":"446_CR27","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/j.1939-1676.2008.0190.x","volume":"22","author":"KA Hahn","year":"2008","unstructured":"Hahn KA, Oglivie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, et al. Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors. J Vet Intern Med. 2008;22:1301\u20139.","journal-title":"J Vet Intern Med"},{"key":"446_CR28","first-page":"2755","volume":"9","author":"CA London","year":"2003","unstructured":"London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res. 2003;9:2755\u201368.","journal-title":"Clin Cancer Res"},{"key":"446_CR29","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1476-5829.2011.00275.x","volume":"10","author":"C London","year":"2012","unstructured":"London C, Mathie T, Stingle N, Clifford C, Haney S, Klein MK, et al. Preliminary evidence for biologic activity of toceranib phosphate (Palladia(\u00ae)) in solid tumours. Vet Comp Oncol. 2012;10:194\u2013205.","journal-title":"Vet Comp Oncol"},{"key":"446_CR30","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-08-1860","volume":"15","author":"CA London","year":"2009","unstructured":"London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res. 2009;15:3856\u201365.","journal-title":"Clin Cancer Res"},{"key":"446_CR31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1476-5810.2004.0053b.x","volume":"2","author":"Veterinary Co-operative Oncology Group (VCOG)","year":"2004","unstructured":"Veterinary Co-operative Oncology Group (VCOG). Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol. 2004;2:195\u2013213.","journal-title":"Vet Comp Oncol"},{"key":"446_CR32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jcpa.2012.11.234","volume":"149","author":"M G\u00f6ritz","year":"2013","unstructured":"G\u00f6ritz M, M\u00fcller K, Krastel D, Staudacher G, Schmidt P, K\u00fchn M, et al. Canine splenic haemangiosarcoma: influence of metastases, chemotherapy and growth pattern on post-splenectomy survival and expression of angiogenic factors. J Comp Pathol. 2013;149:30\u20139.","journal-title":"J Comp Pathol"},{"key":"446_CR33","doi-asserted-by":"publisher","unstructured":"Abou Asa S, Mori T, Maruo K, Khater A, sawak El A, Abd el Aziz E, Yanai T, Sakai H: Analysis of genomic mutation and immunohistochemistry of platelet\u2010derived growth factor receptors in canine vascular tumours. Veterinary and Comparative Oncology 2013. doi:10.1111\/vco.12035.","DOI":"10.1111\/vco.12035"},{"key":"446_CR34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","volume":"15","author":"M P\u00e0ez-Ribes","year":"2009","unstructured":"P\u00e0ez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vi\u00f1als F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220\u201331.","journal-title":"Cancer Cell"},{"key":"446_CR35","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","volume":"15","author":"JML Ebos","year":"2009","unstructured":"Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232\u20139.","journal-title":"Cancer Cell"},{"key":"446_CR36","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/path.4053","volume":"227","author":"M Singh","year":"2012","unstructured":"Singh M, Couto SS, Forrest WF, Lima A, Cheng JH, Molina R, et al. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J Pathol. 2012;227:417\u201330.","journal-title":"J Pathol"},{"key":"446_CR37","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.celrep.2013.01.015","volume":"3","author":"KB Blagoev","year":"2013","unstructured":"Blagoev KB, Wilkerson J, Stein WD, Motzer RJ, Bates SE, Fojo AT. Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma. Cell Rep. 2013;3:277\u201381.","journal-title":"Cell Rep"},{"key":"446_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/1541-7786.MCR-07-0101","volume":"6","author":"A Kadenhe-Chiweshe","year":"2008","unstructured":"Kadenhe-Chiweshe A, Papa J, McCrudden KW, Frischer J, Bae J-O, Huang J, et al. Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation. Mol Cancer Res. 2008;6:1\u20139.","journal-title":"Mol Cancer Res"},{"key":"446_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0002-9440(10)63273-7","volume":"165","author":"T Inai","year":"2004","unstructured":"Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165:35\u201352.","journal-title":"Am J Pathol"},{"key":"446_CR40","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI24612","volume":"116","author":"MR Mancuso","year":"2006","unstructured":"Mancuso MR, Davis R, Norberg SM, O\u2019Brien S, Sennino B, Nakahara T, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006;116:2610\u201321.","journal-title":"J Clin Invest"},{"key":"446_CR41","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/nm.3291","volume":"19","author":"AS Chung","year":"2013","unstructured":"Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med. 2013;19:1114\u201323.","journal-title":"Nat Med"},{"key":"446_CR42","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1083\/jcb.141.7.1659","volume":"141","author":"G Seghezzi","year":"1998","unstructured":"Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci G, Robbins ES, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol. 1998;141:1659\u201373.","journal-title":"J Cell Biol"},{"key":"446_CR43","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/1746-6148-9-190","volume":"9","author":"LF Bernabe","year":"2013","unstructured":"Bernabe LF, Portela R, Nguyen S, Kisseberth WC, Pennell M, Yancey MF, et al. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. BMC Vet Res. 2013;9:190.","journal-title":"BMC Vet Res"},{"key":"446_CR44","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1073\/pnas.0812801106","volume":"106","author":"K Lee","year":"2009","unstructured":"Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci U S A. 2009;106:2353\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"446_CR45","doi-asserted-by":"publisher","unstructured":"Pan X, Tsimbas K, Kurzman ID, Vail DM: Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(\u00ae)) in tumour-bearing dogs: a phase I dose-finding study. Veterinary and Comparative Oncology 2014. doi:10.1111\/vco.12091.","DOI":"10.1111\/vco.12091"},{"key":"446_CR46","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1476-5829.2011.00261.x","volume":"10","author":"C Robat","year":"2012","unstructured":"Robat C, London C, Bunting L, McCartan L, Stingle N, Selting K, et al. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia\u00ae) in dogs: a phase I dose-finding study. Vet Comp Oncol. 2012;10:174\u201383.","journal-title":"Vet Comp Oncol"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12917-015-0446-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-015-0446-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-015-0446-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-015-0446-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T12:43:41Z","timestamp":1748436221000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-015-0446-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,11]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["446"],"URL":"https:\/\/doi.org\/10.1186\/s12917-015-0446-1","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,11]]},"assertion":[{"value":"23 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"131"}}